Filing Flows › Comparisons › SNY vs GSK
Sanofi vs GSK: SNY and GSK compared
Sanofi is the larger company: $11.6B of revenue in its latest quarter (Q2 2026) against $8.0B for GSK (Q2 2026). GSK is more profitable, with an operating margin of 25.3% against 9.0%.
Where the money goes: SNY and GSK
Sanofi (SNY) · Q2 2026
Sanofi, Q2 2026: revenue $11.6B (+16% year over year), operating margin 9.0%, net earnings $377M. The chart follows the revenue to costs, profit and cash.
GSK (GSK) · Q2 2026
GSK, Q2 2026: revenue $8.0B, operating margin 25.3%, net earnings $1.4B. The chart follows the revenue to costs, profit and cash.
| Sanofi (SNY) | GSK (GSK) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $11.6B | $8.0B |
| Revenue growth, Y/Y | +16% | — |
| Gross margin | — | 72.9% |
| Operating margin | 9.0% | 25.3% |
| Net earnings | $377M | $1.4B |
| Net margin | 3.3% | 18.1% |
Where the revenue comes from
GSK
- Specialty Medicines: $3.8B (47%)
- Dolutegravir products: $1.4B (18%)
- Dovato: $749M (9%)
- Nucala: $610M (8%)
Questions
Which is bigger, Sanofi or GSK?
Sanofi is the larger company: $11.6B of revenue in its latest quarter (Q2 2026) against $8.0B for GSK (Q2 2026).
Is Sanofi or GSK growing faster?
GSK is more profitable, with an operating margin of 25.3% against 9.0%.
More: Sanofi earnings · how Sanofi makes money · GSK earnings · how GSK makes money
From the companies' latest 10-Q, 10-K or earnings release (6-K filed Jul 30, 2026; 6-K filed Jul 28, 2026). Fiscal quarters can end on different dates. Not investment advice.